Illumina Inc. (ILMN) agreed to buy GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, in a cash and stock transaction valued at about $8 billion.
The deal consists of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. Illumina currently holds 14.5% of GRAIL's shares outstanding, and approximately 12% on a fully diluted basis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com